Flu season, which begins in January and peaks as late as February or March, arrived in full force early this year. Regular use of a high-quality probiotic, such as Vidazorb®, may help boost the body’s natural defense system, allowing the body to better resist the problems caused by various viruses.
Beltsville, MD January 2013 According to the Centers for Disease Control most of the country is now experiencing “high levels of influenza-like-illness” at levels nearing what have been peak levels of influenza-like illness (ILI) during severe seasons past. With flu season at its height, it’s as important as ever to keep the immune system strong. While following wellness strategies including frequent hand washing and a healthy sleep-and-diet regimen, incorporating Vidazorb® Chewable Probiotics adds another way to help keep “bad bugs” from causing serious problems.
Referred to as “good bacteria”, probiotics help protect the body from the effects of harmful bacteria and viruses. Probiotics can beneficially effect respiratory conditions, help strengthen immunity and even prevent the common cold. Vidazorb® chewable probiotic supplements are a healthy, convenient way to provide bacteria essential to our immune system thus allowing the body to better resist the problems caused by various viruses and bacteria. This can means fewer sick days taken for adults and less child absences from school.
According to Registered Dietitian Mary Hartley, “While it is virtually impossible to completely prevent a cold, you can improve your chances if you stay as healthy as you can. A healthy lifestyle helps to keep your immune system in shape.” She continues, “The immune system’s fight against pathogens starts in your digestive tract, where the helpful bacteria activate immune cells to ward off disease all throughout the body. There is some evidence that certain probiotics may help prevent upper respiratory infections in children and young adults.” And some of those probiotic strains are found in Vidazorb® probiotic formulations.
A randomized, double blind, placebo-controlled study, was conducted by researchers at Luigi Sacco Hospital, Milan, where 211 healthy adults were divided into two probiotic groups (receiving either the BB-12® or L. casei 431® strains) and two control groups receiving placebos. Plasma and saliva samples revealed that the probiotic group participants experienced a significant increase in flu antibodies (twice the baseline) compared with the control groups.
In the BB-12® group 66% of participants had a substantial increase in the antibody IgG3, compared with 4% of the placebo group. Similarly, 46% of the L. casei 431® group experienced a significant increase compared to just 2 percent of the placebo group.
Probiotics are live microorganisms which, when consumed in adequate amounts, provide a health benefit to the host. Everyone naturally has trillions of microorganisms in their intestines, and probiotics — affectionately known as “good bugs” — help maintain a healthy balance of bacteria thus enhancing the immune system by allowing the absorption of anti-oxidants from food, boosting the production of antibodies and supporting a healthier liver and cleaner bloodstream.
Chr. Hansen’s BB-12® is used in five Vidazorb® formulations. In addition to immune strengthening BB-12®, the products also offer consumers other benefits. Vidazorb®’s +OPC and Super C, for instance, were the first successful probiotic supplements in the world containing therapeutic doses of Masquelier’s® Original OPC, which is a powerful source of antioxidants.
Each Vidazorb® supplement is manufactured to the highest quality standards with the full spectrum of bellies in mind. Vidazorb® probiotics are non-refrigerated, calorie-, gluten- and lactose-free in great tasting chewable tablet form.
For the full study, Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study, visit http://journals.cambridge.org/abstract_S000711451100420X